zepbound novo nordisk

Order byBest matchMost fresh

Eli Lilly, Novo Nordisk and Wegovy

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 2d · on MSN

TipRanks on MSN · 2d

Eli Lilly’s Zepbound Defeats Novo Nordisk’s Wegovy Once Again

· 25m

Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 2d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

2don MSN

Here’s how much extra weight is lost with Zepbound over Wegovy

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own treatment, Eli Lilly said of the results presented at the European Congress on Obesity and published in the New England Journal of Medicine.

InvestorsHub on MSN10h

Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna (NASDAQ: SEPN) to co-develop oral small molecule therapies targeting obesity, type 2 diabetes,